Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
暂无分享,去创建一个
M. Banach | N. Wong | K. Kostner | W. Aronow | D. Mikhailidis | P. Muntner | J. Rysz | D. Pella | Steven R. Jones | Z. Fras | S. Nicholls | M. Rizzo | L. Bajnok | R. Češka | D. Mikhailidis | K. Al-Rasadi | K. Ray | M. Davidson | M. Farnier | Michael H. Davidson | D. Nikolić | G. Hovingh | P. Toth | D. Djuric | Vasilis G Athyros | D. Lighezan | M. Ezhov | P. Moriarty | C. Serban | M. Broncel | A. Goudev | R. Puri | R. Greenfield | N. Wong | S. Jones | V. Athyros | D. Djuric | Khalid Al-Rasadi
[1] P. Thompson,et al. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial , 2016, Clinical cardiology.
[2] M. Banach,et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel , 2015, Expert opinion on drug safety.
[3] M. Banach,et al. Contrasting Cholesterol Management Guidelines for Adults with CKD. , 2015, Journal of the American Society of Nephrology : JASN.
[4] M. Banach,et al. Lipids, blood pressure and kidney update 2015 , 2015, Lipids in Health and Disease.
[5] J. Werba,et al. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. , 2015, International journal of cardiology.
[6] Lawrence A Leiter,et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.
[7] Herng‐Ching Lin,et al. Statin use increases the risk of depressive disorder in stroke patients: A population-based study , 2015, Journal of the Neurological Sciences.
[8] G. Lip,et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. , 2015, International journal of cardiology.
[9] P. Thompson,et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. , 2014, Journal of clinical lipidology.
[10] Ž. Reiner. Resistance and intolerance to statins. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[11] B. Gorenek,et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). , 2014, European journal of anaesthesiology.
[12] Susanna Price,et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). , 2014, European heart journal.
[13] Melissa L Hunter,et al. Statin adverse effects: sorting out the evidence. , 2014, The Journal of family practice.
[14] Kreshnik Hoti,et al. Patient attitudes towards a new role for pharmacists: continued dispensing , 2014, Patient preference and adherence.
[15] C. Mantzoros,et al. Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. , 2014, The Journal of clinical endocrinology and metabolism.
[16] J. Kostis,et al. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. , 2014, The journal of sexual medicine.
[17] C. Tseng,et al. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? , 2014, JAMA internal medicine.
[18] Jennifer G. Robinson,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[19] G. Watts,et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.
[20] R. Rosenson,et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.
[21] M. Banach,et al. Statins and new-onset diabetes. , 2014, Current pharmaceutical design.
[22] S. Grundy,et al. An assessment by the Statin Intolerance Panel: 2014 update. , 2014, Journal of clinical lipidology.
[23] N. Chalasani,et al. An assessment by the Statin Liver Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.
[24] O. Franco,et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. , 2014, JAMA.
[25] Ben Goldacre,et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice , 2014, European journal of preventive cardiology.
[26] J. Monson,et al. Perioperative pleiotropic statin effects in general surgery. , 2014, Surgery.
[27] N. Wong. Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .
[28] M. Banach,et al. Lipid, blood pressure and kidney update 2013 , 2014, International Urology and Nephrology.
[29] M. Tonelli,et al. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. , 2014, Annals of internal medicine.
[30] D. Mikhailidis,et al. Are statins ‘IDEAL’ for non-alcoholic fatty liver disease? , 2014, Current medical research and opinion.
[31] F. Mastaglia,et al. Statin myotoxicity: A review of genetic susceptibility factors , 2014, Neuromuscular Disorders.
[32] R. Hegele,et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. , 2013, The Canadian journal of cardiology.
[33] R. May,et al. Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism , 2013, PloS one.
[34] C. Frei,et al. Association of statin use with cataracts: a propensity score-matched analysis. , 2013, JAMA ophthalmology.
[35] K. Madhu,et al. Management of statin intolerance , 2013, Indian journal of endocrinology and metabolism.
[36] M. Pencina,et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? , 2013, International journal of cardiology.
[37] O. Faergeman,et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. , 2013, International journal of cardiology.
[38] E. Lioudaki,et al. Subclinical hypothyroidism and vascular risk: An update , 2013, Hormones.
[39] I. Young,et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[40] Matthew K Ito,et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. , 2013, Journal of clinical lipidology.
[41] M. Chonchol,et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. , 2013, Current pharmaceutical design.
[42] M. Banach,et al. Statin treatment in the elderly: how much do we know? , 2013, Archives of medical science : AMS.
[43] P. Thompson,et al. Statins, exercise, and exercise training. , 2013, Journal of the American College of Cardiology.
[44] M. Banach,et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. , 2013, Current pharmaceutical design.
[45] D. Harats,et al. Intolerance to Statins: Mechanisms and Management , 2013, Diabetes Care.
[46] M. Pencina,et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. , 2013, Pharmacological research.
[47] D. Mikhailidis,et al. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study , 2013, Archives of medical science : AMS.
[48] Tara Gomes,et al. Risk of incident diabetes among patients treated with statins: population based study , 2013, BMJ.
[49] F. Sung,et al. Statin use and risk of hepatocellular carcinoma , 2013, European Journal of Epidemiology.
[50] C. la Vecchia,et al. Statins and primary liver cancer: a meta-analysis of observational studies , 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[51] M. Banach,et al. Statin therapy and new-onset diabetes: an attempt at recommendations , 2013, Expert review of endocrinology & metabolism.
[52] A. Garg,et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases , 2013, BMJ.
[53] B. Cowling,et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials , 2013, BMC Medicine.
[54] M. Landray,et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.
[55] D. Panagiotakos,et al. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study , 2013, The Lancet.
[56] M. Murad,et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. , 2013, Gastroenterology.
[57] V. Gebski,et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. , 2012, JAMA.
[58] Irwin Klein,et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[59] P. Thompson,et al. Effect of Statins on Skeletal Muscle Function , 2012, Circulation.
[60] P. Libby,et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.
[61] DY Gaitonde,et al. Hypothyroidism: an update , 2012, American family physician.
[62] D. Mikhailidis,et al. Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. , 2012, Journal of hepatology.
[63] S. Linnebur,et al. FDA drug safety communications: a narrative review and clinical considerations for older adults. , 2012, The American journal of geriatric pharmacotherapy.
[64] H. van Loveren,et al. Statin-Associated Polymyalgia Rheumatica. An Analysis Using WHO Global Individual Case Safety Database: A Case/Non-Case Approach , 2012, PloS one.
[65] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[66] J. Jónasson,et al. Jaundice Due to Suspected Statin Hepatotoxicity: A Case Series , 2012, Digestive Diseases and Sciences.
[67] M. Abrahamowicz,et al. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: A population‐based study , 2012, Arthritis care & research.
[68] M. Banach,et al. Statin use and risk of diabetes mellitus in postmenopausal women , 2012 .
[69] J. Kastelein,et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial , 2012, European heart journal.
[70] P. Sirvent,et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. , 2012, Toxicology and applied pharmacology.
[71] M. Lapeyre-Mestre,et al. Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database , 2012, Lupus.
[72] T. Bader. Yes! Statins can be given to liver patients. , 2012, Journal of hepatology.
[73] Suzanne G. Leveille,et al. Statin use and musculoskeletal pain among adults with and without arthritis. , 2012, The American journal of medicine.
[74] Evangelos Kalaitzakis,et al. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. , 2012, Journal of hepatology.
[75] Christos G Mihos,et al. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review , 2012, Rheumatology International.
[76] U. Moretti,et al. Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature , 2012, European Journal of Clinical Pharmacology.
[77] P. Thompson,et al. Effect of statins on creatine kinase levels before and after a marathon run. , 2012, The American journal of cardiology.
[78] M. Banach,et al. Lipids, blood pressure, kidney – what was new in 2011? , 2011, Archives of medical science : AMS.
[79] R. Sherafat‐Kazemzadeh,et al. Adolescent with Rhabdomyolysis due to Undiagnosed Hypothyroidism , 2011, Case reports in pediatrics.
[80] H. van Loveren,et al. Use of statins is associated with an increased risk of rheumatoid arthritis , 2011, Annals of the rheumatic diseases.
[81] D. Mikhailidis,et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study , 2011, Archives of medical science : AMS.
[82] C. Glueck,et al. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. , 2011, Medical hypotheses.
[83] P. Kolh,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.
[84] Paul Welsh,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.
[85] Arsh K Jain,et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. , 2011, Journal of the American Society of Nephrology : JASN.
[86] T. Lumley,et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis , 2011, Pharmacogenetics and genomics.
[87] J. Després,et al. Prevention of atherosclerosis in overweight/obese patients. - In need of novel multi-targeted approaches-. , 2011, Circulation journal : official journal of the Japanese Circulation Society.
[88] T. A. Jacobson,et al. Statin-induced myopathy: a review and update , 2011, Expert opinion on drug safety.
[89] D. Mikhailidis,et al. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? , 2011, Annals of medicine.
[90] G. Reach,et al. Statins should be used with greater caution in patients undergoing thyroid hormone withdrawal for radioactive iodine treatment. , 2011, Thyroid.
[91] A. Morris,et al. Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go‐DARTS Study , 2011, Clinical pharmacology and therapeutics.
[92] M. Budoff,et al. Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial , 2011, The American Journal of Gastroenterology.
[93] T. Bader. Liver tests are irrelevant when prescribing statins , 2010, The Lancet.
[94] D. Mikhailidis,et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis , 2010, The Lancet.
[95] R. Collins,et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. , 2010, Lancet.
[96] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[97] M. Banach,et al. Statins in patients with chronic kidney disease: why, who and when? , 2010, Expert opinion on pharmacotherapy.
[98] K. Huey,et al. Statin‐associated myopathy and its exacerbation with exercise , 2010, Muscle & nerve.
[99] J. Jukema,et al. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. , 2010, European journal of internal medicine.
[100] G. Musso,et al. A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.
[101] M. Kaplan,et al. Statins in Primary Biliary Cirrhosis: Are They Safe? , 2010, Digestive Diseases and Sciences.
[102] Carol Coupland,et al. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database , 2010, BMJ : British Medical Journal.
[103] S. Goldberg,et al. Screening stress myocardial perfusion imaging and eligibility for liver transplantation. , 2010, The American journal of cardiology.
[104] M. Banach,et al. The role of Toll-like receptors in renal diseases , 2010, Nature Reviews Nephrology.
[105] W. März,et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. , 2010, Atherosclerosis.
[106] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.
[107] M. Banach,et al. Time for new indications for statins? , 2009, Medical science monitor : international medical journal of experimental and clinical research.
[108] Malte Kelm,et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. , 2009, European heart journal.
[109] Paul M. Ridker,et al. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis , 2009, Diabetes Care.
[110] K. North,et al. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study[S] , 2009, Journal of Lipid Research.
[111] M. Banach,et al. Role and significance of statins in the treatment of hypertensive patients , 2009, Current medical research and opinion.
[112] F. Zoulim,et al. Statins potentiate the in vitro anti‐hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development , 2009, Hepatology.
[113] R. Hegele,et al. Narrative Review: Statin-Related Myopathy , 2009, Annals of Internal Medicine.
[114] W. Aronow,et al. Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions , 2009, American journal of therapeutics.
[115] D. Kivlahan,et al. Alcohol Screening Scores and Medication Nonadherence , 2008, Annals of Internal Medicine.
[116] A. Galina,et al. Cold tolerance in hypothyroid rabbits: role of skeletal muscle mitochondria and sarcoplasmic reticulum Ca2+ ATPase isoform 1 heat production. , 2008, Endocrinology.
[117] Frederick W. Fraunfelder,et al. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. , 2008, Ophthalmology.
[118] S. Lines,et al. Dipstick test for myoglobinuria , 2008, BMJ : British Medical Journal.
[119] G. Wassmer,et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. , 2008, European heart journal.
[120] P. Thompson,et al. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. , 2008, Chest.
[121] D. Mikhailidis,et al. Statin discontinuation: an underestimated risk? , 2008, Current medical research and opinion.
[122] P. Thompson,et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. , 2008, Atherosclerosis.
[123] K. Burman,et al. Two cases of statin-induced myopathy caused by induced hypothyroidism. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[124] J. Dufour,et al. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. , 2008, Swiss medical weekly.
[125] P. Sirvent,et al. New insights into mechanisms of statin-associated myotoxicity. , 2008, Current opinion in pharmacology.
[126] T. Jacobson. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. , 2008, Mayo Clinic proceedings.
[127] J. Kastelein,et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. , 2008, Journal of the American College of Cardiology.
[128] K. Matthews,et al. Lipid-lowering medication use and aggression scores in women: a report from the NHLBI-sponsored WISE study. , 2008, Journal of women's health.
[129] J. Borén,et al. Fatty liver, insulin resistance, and dyslipidemia , 2008, Current diabetes reports.
[130] A. Alshekhlee,et al. Clinical perspectives of statin-induced rhabdomyolysis. , 2007, The American journal of medicine.
[131] J. Armitage,et al. The safety of statins in clinical practice , 2007, The Lancet.
[132] E. Guallar,et al. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.
[133] T. Kiernan,et al. Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism. , 2007, International journal of cardiology.
[134] P. Coriat,et al. The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery , 2007, Anesthesia and analgesia.
[135] R. Demirtunç,et al. Simvastatın improves endothelial function in patents with subclinical hypothyroidism , 2007, Heart and Vessels.
[136] J. Frohlich,et al. Asymptomatic hypothyroidism and statin-induced myopathy. , 2007, Canadian family physician Medecin de famille canadien.
[137] J. Hokanson,et al. Systematic review and meta‐analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present , 2007, Pharmacoepidemiology and drug safety.
[138] B. Noël. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.
[139] B. Riedel,et al. Improved Postoperative Outcomes Associated with Preoperative Statin Therapy , 2006, Anesthesiology.
[140] M. Hennerici,et al. High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.
[141] A. Karlamangla,et al. Moderate alcohol consumption and safety of lovastatin and warfarin among men: the post-coronary artery bypass graft trial. , 2006, The American journal of medicine.
[142] Alicja R Rudnicka,et al. Statin safety: a systematic review. , 2006, The American journal of cardiology.
[143] N. Chalasani,et al. An assessment of statin safety by hepatologists. , 2006, The American journal of cardiology.
[144] P. Thompson,et al. An assessment of statin safety by muscle experts. , 2006, The American journal of cardiology.
[145] H. Bays. Statin safety: an overview and assessment of the data--2005. , 2006, The American journal of cardiology.
[146] E. Bruckert,et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.
[147] E. Hoffman,et al. Changes in Ubiquitin Proteasome Pathway Gene Expression in Skeletal Muscle With Exercise and Statins , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[148] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[149] M. Gale,et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. , 2005, Molecular cell.
[150] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[151] A. M. Marsden,et al. Statin-Induced Muscle Necrosis in the Rat: Distribution, Development, and Fibre Selectivity , 2005, Toxicologic pathology.
[152] Richard Platt,et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.
[153] W. Diemont,et al. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors? , 2004, British journal of clinical pharmacology.
[154] R. Madhok,et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial , 2004, The Lancet.
[155] P. Lindenauer,et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery , 2004, JAMA.
[156] H. Newnham,et al. Successful reintroduction of statin therapy after myositis: was there another cause? , 2004, The Medical journal of Australia.
[157] Deeb N Salem,et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. , 2004, Journal of the American Society of Nephrology : JASN.
[158] L. Mccarthy,et al. Thrombotic Thrombocytopenic Purpura: Yesterday, Today, Tomorrow , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[159] M. Elisaf,et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[160] B. Golomb,et al. Severe irritability associated with statin cholesterol-lowering drugs. , 2004, QJM : monthly journal of the Association of Physicians.
[161] H Sinzinger,et al. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. , 2004, British journal of clinical pharmacology.
[162] C. Abrass. Cellular Lipid Metabolism and the Role of Lipids in Progressive Renal Disease , 2004, American Journal of Nephrology.
[163] L. Teichholz. Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.
[164] R. Fisher,et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.
[165] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[166] S. Grundy. Can Statins Cause Chronic Low-Grade Myopathy? , 2002, Annals of Internal Medicine.
[167] A. Segal. Alopecia associated with atorvastatin. , 2002, The American journal of medicine.
[168] K. Tolman. The liver and lovastatin. , 2002, The American journal of cardiology.
[169] B. Wüthrich,et al. Chronic urticaria to atorvastatin , 2002, Allergy.
[170] G L Freeman,et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.
[171] I. Hamilton-Craig,et al. Statin‐associated myopathy , 2001, The Medical journal of Australia.
[172] G. Boriani,et al. Nightmares and Sleep Disturbances with Simvastatin and Metoprolol , 2001, The Annals of pharmacotherapy.
[173] D. Groneberg,et al. Simvastatin‐induced thrombocytopenia , 2001, American journal of hematology.
[174] L. Hornsby,et al. Dermographism: an adverse effect of atorvastatin. , 2001, The Journal of the American Board of Family Practice.
[175] W. Aronow,et al. Cardiovascular Drug Therapy in the Elderly , 2007, Cardiology in review.
[176] P. Porcu,et al. Thrombotic thrombocytopenic purpura and simvastatin , 1998, The Lancet.
[177] H. Rothberg,et al. Toxic epidermal necrolysis from atorvastatin. , 1998, JAMA.
[178] P. Thompson,et al. Lovastatin increases exercise-induced skeletal muscle injury. , 1997, Metabolism: clinical and experimental.
[179] P. Ducimetiere,et al. Serum cholesterol concentration and death from suicide in men: Paris prospective study I , 1996, BMJ.
[180] T. D. de Bruin,et al. Effects of Alcohol and Fluvastatin on Lipid Metabolism and Hepatic Function , 1995, Annals of Internal Medicine.
[181] K. Kawajiri,et al. Genetic Polymorphisms in the 5 '-Flanking Region Change Transcriptional Regulation of the Human Cytochrome P 45011 E 1 Gene ' , 2008 .
[182] G. Schettler,et al. Cardiovascular Drug Therapy in the Elderly , 1988, Developments in Cardiovascular Medicine.
[183] D. L. Schmucker. Aging and drug disposition: an update. , 1985, Pharmacological reviews.
[184] R. Brady. Disorders of lipid metabolism. , 1972, The Biochemical journal.
[185] L. P. Novâk,et al. Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years. , 1972, Journal of gerontology.
[186] A. Sahebkar,et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. , 2015, Mayo Clinic proceedings.
[187] P. Neufer,et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. , 2012, Free radical biology & medicine.
[188] P. Toth. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .
[189] Ian Graham,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.
[190] E. Requena Carrión,et al. [Renal failure due to simvastatin-induced rhabdomyolysis in a patient with subclinical hypothyroidism]. , 2010, Farmacia Hospitalaria.
[191] M. Banach,et al. Statin therapy in the elderly: a review. , 2010, Archives of gerontology and geriatrics.
[192] E. RequenaCarrión,et al. [Renal failure due to simvastatin-induced rhabdomyolysis in a patient with subclinical hypothyroidism]. , 2010 .
[193] M. Banach,et al. Nephroprotective and clinical potential of statins in dialyzed patients. , 2009, Expert opinion on therapeutic targets.
[194] R. Collins,et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) , 2009 .
[195] A. Vannacci,et al. Statin-Associated Psychiatric Adverse Events , 2008, Drug safety.
[196] H. Takagi,et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. , 2008, European Heart Journal.
[197] N. Kato,et al. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. , 2007, Journal of pharmacological sciences.
[198] J. Farmer. High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.
[199] W. Aronow,et al. Cardiovascular drug therapy in the elderly. , 2007, Cardiology in review.
[200] A. Rabinstein. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .
[201] M. Banach,et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. , 2006, Cellular & molecular immunology.
[202] M. Russo,et al. How to use statins in patients with chronic liver disease. , 2004, Cleveland Clinic journal of medicine.
[203] D. Sica,et al. Rhabdomyolysis and statin therapy: relevance to the elderly. , 2002, The American journal of geriatric cardiology.
[204] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[205] W. Grabski,et al. Pravastatin-induced lichenoid drug eruption. , 1998, Cutis.
[206] P. Elsner,et al. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. , 1993, Dermatology.